• Evaluation théranostique d’un anticorps radiomarqué au cuivre-64 dans un modèle murin de myélome multiple.
    Métivier C, Le Saëc P, Marionneau-Lambot S, Chauvet C, Hofgaard PO, Bogen B, Gaschet J, Tripier R, Haddad F, Chérel M, Chouin N, Faivre-Chauvet A, Rbah-Vidal L
    15èmes Journées annuelles du Cancéropôle Grand-Ouest, Angers, France, 1-2 juillet 2021

  • Theranostic evaluation of a copper-64 radiolabelled antibody in a mouse model of multiple myeloma
    Métivier C, Le Saëc P, Marionneau-Lambot S, Chauvet C, Hofgaard PO, Bogen B, Gaschet J, Tripier R, Haddad F, Chérel M, Chouin N, Faivre-Chauvet A, Rbah-Vidal L
    14th Workshop Adaptation of the tumour and its ecosystem to radiotherapies, Le Bono, France, 22-25 septembre 2021

  • PET imaging of multiple myeloma: Comparison of 89Zr- and 64Cu-labeled anti-CD138 conjugates to 64CuCl2 and 18F-FDG in a preclinical syngeneic model. Bailly C, Gouard S, Chalopin B, Carlier T, Maurel C, Remaud-Le Saëc P, Bourgeois M, Chouin N, Tripier R, Haddad F, Faivre-Chauvet A, Kraeber-Bodéré F, Bodet-Milin C, Chérel M, 7th international workshop on PET in lymphoma and myeloma PIM, Menton, France, October 5-6 2018

    Preliminary results of prognostic added value of PET textural features at diagnosis in multiple myeloma with a long-term follow-up, Carlier T, Jamet B, Bailly C, Touzeau C, Moreau P, Bodet-Milin C, Kraeber-Bodéré F, 7th international workshop on PET in lymphoma and myeloma PIM, Menton, France, October 5-6 2018

    A population pharmacokinetics approach to evaluate the impact of the antibody dose in a context of lymphoma radioimmunotherapy (RIT) on dogs, Morio-Etienne F, Rajaud M, Becavin S, Piccirillo E, Touzot-Jourde G, Vidal A, Bourgeois M, Nguyen F, Abadie J, Varmenot N, Ferrer L, Bodet-Milin C, Ibisch C, Barbet J, Davodeau F, Chouin N, EANM’18 31th Annual congress of the European Association of Nuclear Medicine, Dusseldorf, Germany, oct 13-17 2018